ALG01 / Allygen Biologics - LARVOL DELTA

ALG01, a next-generation anti-PD-L1×TROP-2 bispecific antibody-drug conjugate (BiADC) with STAR technology, demonstrated excellent anti-tumor efficacy & safety in preclinical studies (AACR 2025) - "In toxicology studies, ALG01 was well tolerated in cynomolgus monkeys, with the highest non-severely toxic dose (HNSTD) observed at ≥45 mg/kg for DAR6 or ≥65 mg/kg for DAR4.These preclinical findings indicate that ALG01 offers a wide therapeutic window and may benefit patients with challenging-to-treat cancers. An IND application is planned for submission in 2025."

Preclinical • Oncology